GlyTherix Ltd is a targeted radiotherapy company with a clinical stage product showing an excellent safety profile in high unmet need cancers. Our antibody, Miltuximab® specifically targets GPC-1, a protein found on solid tumours such as prostate, bladder, pancreatic, glioblastoma, oesophageal and ovarian cancers, and is not present in healthy tissue.